Related Experiment Video
Updated: May 26, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Going past the data for temozolomide
J Lee Villano1, Nathalie Letarte, Linda R Bressler
1Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S Wood St Rm 839, M/C 713, Chicago, IL 60612, USA. jvillano@uic.edu
Abstract:
The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Teratogenicity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Overview and Classification

